| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 2/20/2024 | $9.00 | Buy | B. Riley Securities |
| 2/1/2024 | Buy | Jefferies |
Strategic and accretive transaction enables vertical integration of hormone product manufacturing biote Corp. (NASDAQ:BTMD) ("Biote" or the "Company"), a leading solutions provider in preventive health care through the delivery of personalized hormone optimization and therapeutic wellness, today announced a definitive agreement to acquire F.H. Investments, Inc., d/b/a Asteria Health, a privately held 503B manufacturer of compounded bioidentical hormones. The company operates an FDA-registered 503B outsourcing facility in Birmingham, Alabama and currently supports Biote-certified practitioners and Biote-partnered clinics in numerous U.S. states. Through this transaction, Biote is strengt
biote Corp. (NASDAQ:BTMD) ("Biote" or the "Company"), a leading solutions provider in preventive health care through the delivery of personalized hormone optimization and therapeutic wellness, today announced that Robert Peterson has been named Chief Financial Officer, effective January 8, 2024. Mr. Peterson will lead Biote's finance operations, including accounting and controllership, financial planning and analysis, financial reporting, internal audit, tax, treasury and investor relations. Mr. Peterson succeeds Samar Kamdar, who is transitioning to pursue other opportunities, but will remain as an advisor to the Company during a transition period. Mr. Kamdar's transition is unrelated to t
Ms. Puncochar to Drive Execution of Biote's Strategic Sales and Marketing Initiatives biote Corp. (NASDAQ:BTMD) ("Biote" or the "Company"), a leading solutions provider in preventive health care through the delivery of personalized hormone therapy, today announced the appointment of Mary J. Puncochar as Chief Commercial Officer. In this role, Ms. Puncochar will lead Biote's commercial initiatives to expand the Company's presence in the growing market for hormone replacement therapy. Ms. Puncochar joins Biote with more than 30 years of experience in sales, tech-enabled marketing and management roles at leading healthcare, pharmaceutical and medical device companies. Prior to joining Biot
Duke University Oncologist and former Optum Executive Dr. Yousuf Zafar Named Chief Medical OfficerVeteran Digital Health and Commercial Leader Peter Bridges to Serve as Chief Strategy and Growth OfficerDebra Morris Promoted to PresidentDUARTE, Calif., Nov. 13, 2024 /PRNewswire/ -- AccessHope, LLC, a company changing the way leading-edge cancer expertise is delivered, today announced that it is expanding its executive leadership team in response to growing demand for the company's personalized cancer benefit and upcoming product expansion. Yousuf Zafar, MD, MHS, a widely published practicing oncologist from Duke University who brings expertise in value-based care and precision medicine, will
Continued Profitable Growth Vertical integration drives gross profit margin improvement Launch of proprietary clinical decision support software to strengthen competitive advantages Biote (NASDAQ:BTMD), a leading solutions provider in preventive health care through the delivery of personalized hormone optimization and therapeutic wellness, today announced financial results for the third quarter ended September 30, 2024. Third Quarter 2024 Financial Highlights (All financial result comparisons made are against the prior-year period) Revenue of $51.4 million Procedure revenue of $37.9 million Gross profit margin of 70.5% Net income of $12.7 million and diluted earnings per
biote Corp. (NASDAQ:BTMD) ("Biote" or the "Company"), a leading solutions provider in preventive health care through the delivery of personalized hormone optimization and therapeutic wellness, today announced the Company will provide third quarter financial results on Tuesday, November 12, 2024, after the close of the market. A conference call to discuss the firm's results will be held at 5:00 p.m. ET. the same day. Conference Call Details The conference call may be accessed by dialing (844) 481-2820 (U.S toll-free) or (412) 317-0679 (International). The live webcast of the call can be accessed using the following link: biote Corp. Third Quarter Earnings Call. A replay of the webcast will
Procedure revenue growth accelerates sequentially BioteRx roll-out on track with further expansion planned Management reiterates 2024 financial guidance Biote (NASDAQ:BTMD), a leading solutions provider in preventive health care through the delivery of personalized hormone optimization and therapeutic wellness, today announced financial results for the second quarter ended June 30, 2024. Second Quarter 2024 Financial Highlights (All financial result comparisons made are against the prior-year period) Revenue of $49.2 million Procedure revenue of $38.4 million Gross profit margin of 68.9%, including a $1.2 million inventory step-up related to the acquisition of Asteria Healt
biote Corp. (NASDAQ:BTMD) ("Biote" or the "Company"), a leading solutions provider in preventive health care through the delivery of personalized hormone optimization and therapeutic wellness, today announced the Company will provide second quarter financial results on Thursday, August 8, 2024, after the close of the market. A conference call to discuss the firm's results will be held at 5:00 p.m. ET. the same day. Conference Call Details The conference call may be accessed by dialing (844) 481-2820 (U.S toll-free) or (412) 317-0679 (International). The live webcast of the call can be accessed using the following link: biote Corp. Second Quarter Earnings Call. A replay of the webcast wi
biote Corp. (NASDAQ:BTMD) ("Biote" or the "Company"), a leading solutions provider in preventive health care through the delivery of personalized hormone optimization and therapeutic wellness, today announced it has signed a binding term sheet with Marci M. Donovitz, stockholder of Biote, to resolve litigation ("Donovitz Litigation"). For $60 million in the aggregate, Biote will repurchase all of the approximately 8.3 million of the Paired Interests and/or Class A Shares, as applicable, owned by Ms. Donovitz and will release and cancel all of the approximately 4.0 million Paired Interests subject to contractual earnout provisions ("earnout shares") owned by Ms. Donovitz for no additional mo
Procedure revenue growth and strengthened profitability drive solid financial performance Phased launch of BioteRx remains on track Reaffirms 2024 financial guidance, with an acceleration in second half growth Biote (NASDAQ:BTMD), a leading solutions provider in preventive health care through the delivery of personalized hormone optimization and therapeutic wellness, today announced financial results for the first quarter ended March 31, 2024. First Quarter 2024 Financial Highlights (All financial result comparisons made are against the prior-year period) Revenue of $46.8 million, up 4.4% Procedure revenue of $37.4 million, up 6.6% Gross profit margin of 71.4%, an approxima
Company to repurchase all of Founder's 18.4 million shares at $4.17 per share biote Corp. (NASDAQ:BTMD) ("Biote" or the "Company"), a leading solutions provider in preventive health care through the delivery of personalized hormone optimization and therapeutic wellness, today announced it has entered into a definitive settlement agreement (the "Settlement Agreement") that concludes outstanding litigation with Dr. Gary S. Donovitz ("Donovitz"), founder and stockholder of Biote. The Settlement Agreement includes a mutual release of all claims relating to litigation between Donovitz and Biote; the termination of the founder advisory agreement by and between Donovitz and BioTE Medical, LLC;
biote Corp. (NASDAQ:BTMD) ("Biote" or the "Company"), a leading solutions provider in preventive health care through the delivery of personalized hormone optimization and therapeutic wellness, today announced the Company will provide first quarter financial results on Tuesday, May 7, 2024, after the close of the market. A conference call to discuss the firm's results will be held at 5:00 p.m. ET. the same day. Conference Call Details The conference call may be accessed by dialing (844) 481-2820 (U.S toll-free) or (412) 317-0679 (International). The live webcast of the call can be accessed using the following link: biote Corp. First Quarter Earnings Call. A replay of the webcast will be
Grew practitioner network to over 7,100 from 6,400 in 2022 Launched BioteRx, our new hormone and therapeutic wellness offerings Enhancing shareholder value with agreement to repurchase 18.4M founders' shares in addition to a separate $20M share repurchase program Reaffirms 2024 financial guidance, with an acceleration in second half growth Biote (NASDAQ:BTMD), a leading solutions provider in preventive health care through the delivery of personalized hormone optimization and therapeutic wellness, today announced financial results for the fourth quarter and full year ended December 31, 2023. Fourth Quarter 2023 Financial Highlights (All financial result comparisons made are against
Continued Profitable Growth Vertical integration drives gross profit margin improvement Launch of proprietary clinical decision support software to strengthen competitive advantages Biote (NASDAQ:BTMD), a leading solutions provider in preventive health care through the delivery of personalized hormone optimization and therapeutic wellness, today announced financial results for the third quarter ended September 30, 2024. Third Quarter 2024 Financial Highlights (All financial result comparisons made are against the prior-year period) Revenue of $51.4 million Procedure revenue of $37.9 million Gross profit margin of 70.5% Net income of $12.7 million and diluted earnings per
biote Corp. (NASDAQ:BTMD) ("Biote" or the "Company"), a leading solutions provider in preventive health care through the delivery of personalized hormone optimization and therapeutic wellness, today announced the Company will provide third quarter financial results on Tuesday, November 12, 2024, after the close of the market. A conference call to discuss the firm's results will be held at 5:00 p.m. ET. the same day. Conference Call Details The conference call may be accessed by dialing (844) 481-2820 (U.S toll-free) or (412) 317-0679 (International). The live webcast of the call can be accessed using the following link: biote Corp. Third Quarter Earnings Call. A replay of the webcast will
Procedure revenue growth accelerates sequentially BioteRx roll-out on track with further expansion planned Management reiterates 2024 financial guidance Biote (NASDAQ:BTMD), a leading solutions provider in preventive health care through the delivery of personalized hormone optimization and therapeutic wellness, today announced financial results for the second quarter ended June 30, 2024. Second Quarter 2024 Financial Highlights (All financial result comparisons made are against the prior-year period) Revenue of $49.2 million Procedure revenue of $38.4 million Gross profit margin of 68.9%, including a $1.2 million inventory step-up related to the acquisition of Asteria Healt
biote Corp. (NASDAQ:BTMD) ("Biote" or the "Company"), a leading solutions provider in preventive health care through the delivery of personalized hormone optimization and therapeutic wellness, today announced the Company will provide second quarter financial results on Thursday, August 8, 2024, after the close of the market. A conference call to discuss the firm's results will be held at 5:00 p.m. ET. the same day. Conference Call Details The conference call may be accessed by dialing (844) 481-2820 (U.S toll-free) or (412) 317-0679 (International). The live webcast of the call can be accessed using the following link: biote Corp. Second Quarter Earnings Call. A replay of the webcast wi
Procedure revenue growth and strengthened profitability drive solid financial performance Phased launch of BioteRx remains on track Reaffirms 2024 financial guidance, with an acceleration in second half growth Biote (NASDAQ:BTMD), a leading solutions provider in preventive health care through the delivery of personalized hormone optimization and therapeutic wellness, today announced financial results for the first quarter ended March 31, 2024. First Quarter 2024 Financial Highlights (All financial result comparisons made are against the prior-year period) Revenue of $46.8 million, up 4.4% Procedure revenue of $37.4 million, up 6.6% Gross profit margin of 71.4%, an approxima
biote Corp. (NASDAQ:BTMD) ("Biote" or the "Company"), a leading solutions provider in preventive health care through the delivery of personalized hormone optimization and therapeutic wellness, today announced the Company will provide first quarter financial results on Tuesday, May 7, 2024, after the close of the market. A conference call to discuss the firm's results will be held at 5:00 p.m. ET. the same day. Conference Call Details The conference call may be accessed by dialing (844) 481-2820 (U.S toll-free) or (412) 317-0679 (International). The live webcast of the call can be accessed using the following link: biote Corp. First Quarter Earnings Call. A replay of the webcast will be
Grew practitioner network to over 7,100 from 6,400 in 2022 Launched BioteRx, our new hormone and therapeutic wellness offerings Enhancing shareholder value with agreement to repurchase 18.4M founders' shares in addition to a separate $20M share repurchase program Reaffirms 2024 financial guidance, with an acceleration in second half growth Biote (NASDAQ:BTMD), a leading solutions provider in preventive health care through the delivery of personalized hormone optimization and therapeutic wellness, today announced financial results for the fourth quarter and full year ended December 31, 2023. Fourth Quarter 2023 Financial Highlights (All financial result comparisons made are against
biote Corp. (NASDAQ:BTMD) ("Biote" or the "Company"), a leading solutions provider in preventive health care through the delivery of personalized hormone optimization and therapeutic wellness, today announced the Company will provide fourth quarter and full year financial results on Tuesday, March 12, 2024, after the close of the market. A conference call to discuss the firm's results will be held at 5:00 p.m. ET. the same day. Conference Call Details The conference call may be accessed by dialing (844) 481-2820 (U.S toll-free) or (412) 317-0679 (International). The live webcast of the call can be accessed using the following link: biote Corp. Fourth Quarter Earnings Call. A replay of t
biote Corp. (NASDAQ:BTMD) ("Biote" or the "Company"), a leading solutions provider in preventive health care through the delivery of personalized hormone optimization and therapeutic wellness, today announced that management expects 2023 revenue and Adjusted EBITDA to be slightly below prior guidance. The Company had previously forecast that revenue and Adjusted EBITDA would be toward the lower end of the previously announced ranges of $190-$200 million and $56-$60 million, respectively. The Company now expects full year 2023 revenue of $185-$187 million and Adjusted EBITDA of $54-$56 million. The Company's expected 2023 revenue growth of approximately 12% over the prior year includes pro
Achieves Progress in Test of Complementary Wellness Therapeutics Reiterates 2023 Financial Guidance Biote (NASDAQ:BTMD), a leading solutions provider in preventive health care through the delivery of personalized hormone therapy, today announced financial results for the third quarter ended September 30, 2023. Third Quarter 2023 Financial Highlights (All financial result comparisons made are against the prior year period) Revenue of $45.6 million, an 8.5% increase Gross profit margin of 68.9%, a 70-basis point increase Net income of $19.6 million, representing net income margin of 43.1%, and basic earnings per share of $0.25, compared to net income of $0.5 million, represen
B. Riley Securities initiated coverage of biote Corp. with a rating of Buy and set a new price target of $9.00
Jefferies initiated coverage of biote Corp. with a rating of Buy
424B3 - biote Corp. (0001819253) (Filer)
424B3 - biote Corp. (0001819253) (Filer)
10-Q - biote Corp. (0001819253) (Filer)
8-K - biote Corp. (0001819253) (Filer)
424B3 - biote Corp. (0001819253) (Filer)
424B3 - biote Corp. (0001819253) (Filer)
10-Q - biote Corp. (0001819253) (Filer)
8-K - biote Corp. (0001819253) (Filer)
8-K - biote Corp. (0001819253) (Filer)
8-K - biote Corp. (0001819253) (Filer)
4 - biote Corp. (0001819253) (Issuer)
4 - biote Corp. (0001819253) (Issuer)
4/A - biote Corp. (0001819253) (Issuer)
4 - biote Corp. (0001819253) (Issuer)
4 - biote Corp. (0001819253) (Issuer)
4 - biote Corp. (0001819253) (Issuer)
4 - biote Corp. (0001819253) (Issuer)
4 - biote Corp. (0001819253) (Issuer)
4 - biote Corp. (0001819253) (Issuer)
4 - biote Corp. (0001819253) (Issuer)
For $60 million in the aggregate, Biote will repurchase all of the approximately 8.3 million of the Paired Interests and/or Class A Shares, as applicable, owned by Ms. Donovitz and will release and cancel all of the approximately 4.0 million Paired Interests subject to contractual earnout provisions ("earnout shares") owned by Ms. Donovitz for no additional monetary consideration. Biote intends to fund the repurchases in accordance with its existing capital allocation strategy.
2024 Financial Outlook"Based on our solid first quarter financial performance and our expectations for stronger revenue growth in the second half of the year, we reaffirm our 2024 financial guidance," concluded Ms. Weber.($ in millions)Previously Reported 2024 Guidance RangesRevenue$200-$204Adjusted EBITDA1$60-$63
Biote (NASDAQ:BTMD) reported quarterly losses of $(0.06) per share which missed the analyst consensus estimate of $0.03 by 300 percent. This is a 84.62 percent increase over losses of $(0.39) per share from the same period last year. The company reported quarterly sales of $46.804 million which beat the analyst consensus estimate of $45.711 million by 2.39 percent. This is a 4.37 percent increase over sales of $44.843 million the same period last year.
Company to repurchase all of Founder's 18.4 million shares at $4.17 per sharebiote Corp. (NASDAQ:BTMD) ("Biote" or the "Company"), a leading solutions provider in preventive health care through the delivery of personalized hormone optimization and therapeutic wellness, today announced it has entered into a definitive settlement agreement (the "Settlement Agreement") that concludes outstanding litigation with Dr. Gary S. Donovitz ("Donovitz"), founder and stockholder of Biote.The Settlement Agreement includes a mutual release of all claims relating to litigation between Donovitz and Biote; the termination of the founder advisory agreement by and between Donovitz and BioTE Medical, LLC; two ye
Gainers Qilian Intl Hldg Gr (NASDAQ:QLI) shares rose 63.8% to $1.04 during Friday's after-market session. The market value of their outstanding shares is at $37.1 million. Sunshine Biopharma (NASDAQ:SBFM) stock moved upwards by 39.5% to $0.08. The company's market cap stands at $8.3 million. Galera Therapeutics (NASDAQ:GRTX) shares increased by 28.57% to $0.18. The company's market cap stands at $9.7 million. As per the news, the Q4 earnings report came out yesterday. Medpace Hldgs (NASDAQ:MEDP) shares rose 18.76% to $480.0. The market value of their outstanding shares is at $14.7 billion. Xilio Therapeutics (NASDAQ:XLO) shares rose 17.59% to $1.29. The company's market cap stands at $3
Roth MKM analyst George Kelly reiterates Biote (NASDAQ:BTMD) with a Buy and raises the price target from $8 to $9.
Previously, Biote projected fiscal 2024 revenue of greater than $200 million and Adjusted EBITDA of greater than $60 million. First half 2024 consolidated year-on-year revenue growth is expected to be in the low-single digits, with significant improvement expected in the second half of 2024. Total revenue growth in the first half of 2024 is expected to be impacted by the transition in the nutraceutical distribution channel and timing of seasonal promotions.
Biote (NASDAQ:BTMD) reported its Q4 earnings results on Tuesday, March 12, 2024 at 04:05 PM. Here's what investors need to know about the announcement. Earnings Biote beat estimated earnings by 125.0%, reporting an EPS of $0.18 versus an estimate of $0.08. Revenue was up $1.22 million from the same period last year. Past Earnings Performance Last quarter the company beat on EPS by $0.17 which was followed by a 24.0% drop in the share price the next day. Here's a look at Biote's past performance: Quarter Q3 2023 Q2 2023 Q1 2023 Q4 2022 EPS Estimate 0.07 0.09 0.09 0.14 EPS Actual 0.24 -0.25 -0.39 0.18 Revenue Estimate 47.90M 46.76M 43.47M 43.73M Revenue Actual 45.56M 49.26M 44.84M
SC 13G/A - biote Corp. (0001819253) (Subject)
SC 13G/A - biote Corp. (0001819253) (Subject)
SC 13G/A - biote Corp. (0001819253) (Subject)
SC 13G/A - biote Corp. (0001819253) (Subject)
SC 13G/A - biote Corp. (0001819253) (Subject)
SC 13G/A - biote Corp. (0001819253) (Subject)
SC 13G/A - biote Corp. (0001819253) (Subject)
SC 13D - biote Corp. (0001819253) (Subject)
SC 13G - biote Corp. (0001819253) (Subject)
SC 13G - biote Corp. (0001819253) (Subject)